http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106029905-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate | 2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106029905-B |
| titleOfInvention | Design of rationale-based cancer-targeted therapies |
| abstract | The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces the level and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for using lestaurtinib to down-regulate one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof. |
| priorityDate | 2013-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 612.